Elixir Medical Corporation company information, Employees & Contact Information

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care The Manila Times

Elixir Medical Announces Key Commercial Milestone With GlobeNewswire

Elixir Medical Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025 Business Wire

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia Koreabizwire

Elixir Medical’s DynamX Sirolimus-Eluting coronary bioadaptor system receives US FDA Breakthrough Device Designation Yahoo Finance

Elixir Medical Announces Launch of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe GlobeNewswire

Coronary Bioadaptor Systems Demonstrates Significant Improvement for Patients with ACS, Complex Lesion Subsets Diagnostic and Interventional Cardiology

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor Diagnostic and Interventional Cardiology

TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and Intervention Business Wire

EuroPCR Late-Breaking Clinical Trial Data Finds Effectiveness of Elixir Medical’s DynamX Bioadaptor for PCI Treatment Diagnostic and Interventional Cardiology

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success Diagnostic and Interventional Cardiology

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial Business Wire

Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES Diagnostic and Interventional Cardiology

Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months Business Wire

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease Diagnostic and Interventional Cardiology

Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023 Diagnostic and Interventional Cardiology

Elixir Medical Completes Enrollment in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System Diagnostic and Interventional Cardiology

Six-Month Clinical Data from DESyne BDS Plus Randomized Controlled Trial (RCT) Presented at TCT 2023 Shines Spotlight on Safety, Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy Diagnostic and Interventional Cardiology

DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study Diagnostic and Interventional Cardiology

Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent MassDevice

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained GlobeNewswire

Elixir Medical announces full LithiX IVL rollout in Europe MassDevice

Elixir Medical launches IVL system in Europe MassDevice

Elixir Receives European Approval for Fully Bioresorbable Novolimus-eluting Coronary Stent Diagnostic and Interventional Cardiology

Elixir Completes First Commercial Implant Of Fully Bioresorbable Stent Diagnostic and Interventional Cardiology

Elixir Gains European Approval for Fully Bioresorbable Drug-Eluting Coronary Stent Diagnostic and Interventional Cardiology

DESolve I First-In-Man Study Positive for the Fully Bioresorbable Drug-Eluting Coronary Stent Diagnostic and Interventional Cardiology